StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.46−0.06 (-1.70%)

Close on Nov 17, 2026Market cap $224.08MP/E –Yield –

Immuneering revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Immuneering's revenue for the twelve months ending Dec 31, 2023 was $0, down 100.0% year over year. For fiscal 2023 it was $0, down 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$316.95K-84.8%
FY2021Dec 31, 2021$2.08M-10.0%
FY2020Dec 31, 2020$2.31M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$455-99.8%
Q3 FY2022Sep 30, 2022$38.38K-92.0%
Q2 FY2022Jun 30, 2022$94.42K-85.7%
Q1 FY2022Mar 31, 2022$183.70K-75.4%
Q4 FY2021Dec 31, 2021$189.59K-71.5%
Q3 FY2021Sep 30, 2021$482.13K-29.4%
Q2 FY2021Jun 30, 2021$660.04K+37.3%
Q1 FY2021Mar 31, 2021$748.20K–
Q4 FY2020Dec 31, 2020$665.08K–
Q3 FY2020Sep 30, 2020$682.57K–
Q2 FY2020Jun 30, 2020$480.84K–

More Immuneering figures

See a number that looks wrong?